Tolebrutinib has been approved in the European Union for the treatment of secondary progressive multiple sclerosis (SPMS) for people who have not experienced a relapse in the previous two years. The medication will be sold under the brand name Cenrifki. The decision, which is in line with a…
tolebrutinib
Recommended Posts
- How functional dentistry can help to reduce immune and toxic stress
- Study connects lower levels of rare gut bacterium to higher MS risk
- Childhood trauma may affect treatment adherence in MS patients
- Like the spoon theory, the fork theory can also help explain MS
- 2 brain MRI markers may help ID MS patients at risk of cognitive decline